Covid Virus Articles & Analysis
73 news found
The project has the goal to develop a “Pan-protective SARS-CoV-2 vaccine” hoping to show protection against all past and future variant of concern of the Corona virus. Initiated 2020 by ExcellGene’s research and funded since April 2022 deep insights into the immunogenicity of the various COVID virus variants have emerged. ...
The ongoing COVID-19 pandemic necessitates the need for robust and reliable detection methods to tackle the spread of the virus and to alleviate the severe socio-economic consequences of the disease. Alertgy has partnered with Florida Atlantic University’s (FAU) Immunology and Virology Department to execute a collaborative study on the diagnostic ...
ByAlertgy
Alertgy plans to focus on non-invasive glucose monitoring of non-insulin dependent Type 2 diabetics and pre-diabetics during its FDA clinical trials. COVID Detection Alertgy’s patented RF sensor technology has the potential to detect molecules other than glucose, both inside the body and in lab-based settings. For this reason, Alertgy is partnering with Florida Atlantic ...
ByAlertgy
Viral Vaccine Manufacturing to control pandemics: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has created a global public health crisis. ...
ByNuvonis
This drug, produced in spirulina, contains an antibody cocktail for SARS-CoV-2, the virus that causes COVID-19. Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the ...
In the past year miDiagnostics has been working on the development of an ultra-fast PCR test based on imec technology, to detect COVID-19, with a test result in less than 15 minutes. In cooperation with Brussels Airport, this nasal-swab ultra-fast PCR test, as well as the new breath sampler developed by imec and licensed by miDiagnostics, will be tested in practice during a study ...
In November 2021, the company was awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative to accelerate the launch and broad market availability of the AscencioDx™ molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus. ...
The planned clinical site in Serbia will not be participating in the study due to staffing capacity issues related to the ongoing impact of the COVID-19 virus. “We are pleased that the initial safety data from InMed’s Phase 2 EB clinical trial has allowed the inclusion of adolescent patients,” stated Alexandra Mancini, Senior Vice President of ...
Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. ...
EPA recommends the use of disinfectants to inactivate the SARS-CoV-2 (COVID-19) virus. Matter-of-factly, QACs are active ingredients in over 200 disinfectants. ...
Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic platform for the detection of RNA indicative of the presence of the SARS-CoV-2/COVID-19 virus, to the Food and Drug Administration (FDA). Anavasi is a medical technology company focused on the development of novel ...
The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy. “As the COVID-19 virus continues to evolve, so does our understanding of the efficacy of vaccines and the critical role they play in protecting people from serious disease, hospitalization and ...
The Agreement is for an initial pre-order of 10 million doses of oral COVID-19 vaccines from Oravax and is comprised of milestone payments. ...
(www.ora-vax.com), has screened and enrolled the first participant in a Phase 1 clinical trial of its oral virus-like particle (VLP) COVID-19 vaccine in Johannesburg, South Africa. The open-label trial anticipates enrolling 24 participants who have not received either a COVID-19 vaccine or contracted the virus. Participants will ...
Emergency rations. And, just maybe, some future COVID-19 vaccines. Freeze-drying is a method for removing water from a product. ...
This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity. ...
ByAerogen
The funding will accelerate the launch and broad market availability of the AscencioDx™ molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus. Currently in clinical trials in the U.S., Anavasi expects to file its submission to the U.S. ...
As we all know, this has been a special year for everyone. This difficult period is making us experience new situations and emotions that until recently we would never have ...
For the time being, we are doing our best to help limiting the spread of the Corona virus (COVID-19) in Germany and globally. Actually, there is no Corona virus infection known within our company. ...
According to the World Health Organization, “People in close contact with someone who is infected with a virus, such as the Ebola or COVID virus, are at higher risk of becoming infected themselves, and of potentially further infecting others. ...
ByBioVigil